Allarity Therapeutics, Inc.
ALLR
$1.52
-$0.16-9.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.94% | -27.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.59% | -39.08% | |||
| Operating Income | -15.89% | 39.08% | |||
| Income Before Tax | -20.21% | -20.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.21% | -20.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.21% | -20.95% | |||
| EBIT | -15.89% | 39.08% | |||
| EBITDA | -16.12% | 39.19% | |||
| EPS Basic | -10.98% | -27.53% | |||
| Normalized Basic EPS | -10.92% | -27.55% | |||
| EPS Diluted | -10.98% | -27.53% | |||
| Normalized Diluted EPS | -10.92% | -27.55% | |||
| Average Basic Shares Outstanding | 8.32% | -5.17% | |||
| Average Diluted Shares Outstanding | 8.32% | -5.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||